Document is current
Any future updates will be listed below
-
Authors
Shah, Viral S.
Waghray, Avinash
Lin, Brian https://orcid.org/0000-0002-8851-3534
Bhagwat, Atharva https://orcid.org/0009-0004-7311-0283
Monga, Isha https://orcid.org/0000-0002-4683-9456
Slyper, Michal
Giotti, Bruno
Kim, Sunghyun
Sun, Dawei
Xu, Ke https://orcid.org/0000-0002-0621-4507
Park, Eric
Bairakdar, Mohamad
Xu, Jiajie
Waldman, Julia
Dionne, Danielle https://orcid.org/0000-0002-8338-4323
Nguyen, Lan T.
Lou, Wendy
Cai, Peiwen https://orcid.org/0000-0003-4774-4392
Muus, Christoph
Sun, Jiawei
Surve, Manalee V.
Yang, Lujia Cha Cha
Rozenblatt-Rosen, Orit https://orcid.org/0000-0001-6313-3570
Delorey, Toni M. https://orcid.org/0000-0001-6614-3803
Saladi, Srinivas Vinod https://orcid.org/0000-0001-8147-4379
Regev, Aviv https://orcid.org/0000-0003-3293-3158
Rajagopal, Jayaraj https://orcid.org/0000-0002-4122-177X
Tsankov, Alexander M. https://orcid.org/0000-0002-7955-4414
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (5R01HL164563, 5R01HL15722, 5T32HL116275, U24HL148865-04, U24HL148865-01, R56HL157632, R21HL156124)
Cystic Fibrosis Foundation (003338L121, Lin19F0, TSANKO20G0)
- License Information
-
More Information
Article History
Received: 26 March 2025
Accepted: 26 May 2025
First Online: 4 June 2025
Competing interests
: Aviv Regev is a founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas Therapeutics, and until August 31, 2020, was a SAB member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov and Thermo Fisher Scientific. From August 1, 2020, Aviv Regev has been an employee of Genentech and has equity in Roche. Avinash Waghray is an employee of Immunology and Inflammation Research Therapeutic Area, Sanofi, Cambridge, MA. Srinivas Vinod Saladi is a co-founder of Reinwik Inc. Brian Lin is a consultant for Rhino Therapeutics and a co-founder of Cellsor. The remaining authors declare no competing interests.
